LIDDS participates in BIO International Convention 2022

Non Regulatory

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company's CEO Nina Herne and CSO Matthew Lindon will participate in the Biotech International Convention, also known as US BIO, between 13 and 16 June 2022.

LIDDS’ CEO Nina Herne and CSO Matthew Lindon participate in the US BIO, which is physically organized in San Diego, California after two years of digital events. US BIO is the world's largest meeting place for companies in the pharmaceutical and biotechnology sectors and provides opportunities for both collaboration and partner discussions as well as investor meetings. In total, more than 3,000 companies from more than 30 countries participate.

For additional information, please contact

Nina Herne, CEO
Phone: +46 (0)70 714 74 57
E-mail: nina.herne@liddspharma.com
 
Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB
Tel: +46 (0)8 121 576 90
E-mail: certifiedadviser@redeye.se

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS participates in BIO International Convention 2022